MYSM1 and cataract: It was noticed that 3 AAV9‐Ctrl‐treated animals developed dull and partially white eyes, cataracts, and eye diseases at 18, 19, and 20 months of age, while all of the AAV9‐Mysm1‐treated mice showed no signs of eye diseases (Figure 6G).